Filed Pursuant to Rule 433
Registration Statement 333-236351
February 18, 2020
Amgen Inc.
PRICING TERM SHEET
Dated February 18, 2020
$500,000,000 1.900% Senior Notes due 2025 (the “2025” Notes)
$750,000,000 2.200% Senior Notes due 2027 (the “2027” Notes)
$1,250,000,000 2.450% Senior Notes due 2030 (the “2030” Notes)
$1,250,000,000 3.150% Senior Notes due 2040 (the “2040” Notes)
$1,250,000,000 3.375% Senior Notes due 2050 (the “2050” Notes)
This term sheet relates only to the securities described below and supplements and should be read together with the preliminary prospectus supplement, dated February 18, 2020, and the accompanying prospectus (including the documents incorporated by reference in the accompanying prospectus) relating to these securities.
| Issuer: | Amgen Inc. | |
| Ranking: | Senior Unsecured | |
| Principal Amount: | 2025 Notes: $500,000,000 aggregate principal amount 2027 Notes: $750,000,000 aggregate principal amount 2030 Notes: $1,250,000,000 aggregate principal amount 2040 Notes: $1,250,000,000 aggregate principal amount 2050 Notes: $1,250,000,000 aggregate principal amount | |
| Maturity Date: | 2025 Notes: February 21, 2025 2027 Notes: February 21, 2027 2030 Notes: February 21, 2030 2040 Notes: February 21, 2040 2050 Notes: February 21, 2050 | |
| Coupon: | 2025 Notes: 1.900% per annum, accruing from and including February 21, 2020 2027 Notes: 2.200% per annum, accruing from and including February 21, 2020 2030 Notes: 2.450% per annum, accruing from and including February 21, 2020 2040 Notes: 3.150% per annum, accruing from and including February 21, 2020 2050 Notes: 3.375% per annum, accruing from and including February 21, 2020 | |
| Price to Public: | 2025 Notes: 99.796% of principal amount 2027 Notes: 99.787% of principal amount 2030 Notes: 99.965% of principal amount 2040 Notes: 99.603% of principal amount 2050 Notes: 99.962% of principal amount | |
| Benchmark Treasury: | 2025 Notes: 1.375% due January 31, 2025 2027 Notes: 1.500% due January 31, 2027 2030 Notes: 1.500% due February 15, 2030 2040 Notes: 2.375% due November 15, 2049 2050 Notes: 2.375% due November 15, 2049 | |
1
| Benchmark Treasury Price / Yield: |
2025 Notes: 99-291⁄4 / 1.393% 2027 Notes: 100-03+ / 1.483% 2030 Notes: 99-16 / 1.554% 2040 Notes: 108-06+ / 2.007% 2050 Notes: 108-06+ / 2.007% | |
| Spread to Benchmark: | 2025 Notes: 55 bps 2027 Notes: 75 bps 2030 Notes: 90 bps 2040 Notes: 117 bps 2050 Notes: 137 bps | |
| Yield to Maturity: | 2025 Notes: 1.943% 2027 Notes: 2.233% 2030 Notes: 2.454% 2040 Notes: 3.177% 2050 Notes: 3.377% | |
| Interest Payment Dates: | 2025 Notes: February 21 and August 21 of each year, commencing on August 21, 2020 2027 Notes: February 21 and August 21 of each year, commencing on August 21, 2020 2030 Notes: February 21 and August 21 of each year, commencing on August 21, 2020 2040 Notes: February 21 and August 21 of each year, commencing on August 21, 2020 2050 Notes: February 21 and August 21 of each year, commencing on August 21, 2020 | |
| Reinvestment Rate (for make whole call): | 2025 Notes: 10 bps; 2027 Notes: 15 bps; 2030 Notes: 15 bps; 2040 Notes: 20 bps; 2050 Notes: 25 bps;
in each case plus the weekly yield for the most recent week set forth in the most recent Statistical Release for the constant maturity U.S. Treasury security (rounded to the nearest month) corresponding to the remaining life to maturity, as of the payment date of the principal being redeemed or paid. | |
| Par Call Dates: | 2025 Notes: January 21, 2025 2027 Notes: December 21, 2026 2030 Notes: November 21, 2029 2040 Notes: August 21, 2039 2050 Notes: August 21, 2049 | |
| Trade Date: | February 18, 2020 | |
| Settlement Date: | February 21, 2020 (T+3) | |
| CUSIP / ISIN: | 2025 Notes: 031162 CV0 / US031162CV00 2027 Notes: 031162 CT5 / US031162CT53 2030 Notes: 031162 CU2 / US031162CU27 2040 Notes: 031162 CR9 / US031162CR97 2050 Notes: 031162 CS7 / US031162CS70 | |
| Denominations: | $2,000 x $1,000 | |
| Expected Ratings*: | Baa1 (stable) / A- (stable) (Moody’s / S&P) | |
2
| Joint Book-Running Managers: | Citigroup Global Markets Inc. Goldman Sachs & Co. LLC Barclays Capital Inc. BofA Securities, Inc. J.P. Morgan Securities LLC HSBC Securities (USA) Inc. Mizuho Securities USA LLC | |
| Co-Managers: | BNP Paribas Securities Corp. Credit Suisse Securities (USA) LLC Deutsche Bank Securities Inc. MUFG Securities Americas Inc. RBC Capital Markets, LLC Sumitomo Mitsui Financial Group, Inc. Wells Fargo Securities, LLC Samuel A. Ramirez & Company, Inc. | |
Changes to Preliminary Prospectus Supplement
The second paragraph of the section entitled “Use of Proceeds” is revised in its entirety to read as set forth below. (Additional conforming changes will be made to the Preliminary Prospectus Supplement consistent with these changes.)
“We intend to use the net proceeds from this offering to (i) redeem in full our outstanding 3.45% Senior Notes due 2020 in an aggregate outstanding principal amount of $900 million, which have a stated maturity date of October 1, 2020, (ii) redeem in full our 4.10% Senior Notes due 2021 in an aggregate outstanding principal amount of $1.0 billion, which have a stated maturity date of June 15, 2021, (iii) redeem in full our 1.85% Senior Notes due 2021 in an aggregate outstanding principal amount of $750 million, which have a stated maturity date of August 19, 2021 and (iv) redeem $300 million aggregate principal amount of our 3.875% Senior Notes due 2021 (of which $1.75 billion aggregate principal amount of such Notes is currently outstanding), which have a stated maturity date of November 15, 2021. The redemption of each series of notes will include the payment of a make-whole amount and accrued and unpaid interest on the notes to, but not including, the date of redemption. We intend to use any remaining net proceeds from this offering to repay our outstanding indebtedness and for general corporate purposes.”
Amgen Inc. has filed a registration statement (including a prospectus dated as of February 10, 2020) and a prospectus supplement dated as of February 18, 2020 with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents Amgen Inc. has filed with the SEC for more complete information about the issuer and this offering. You should rely on the prospectus, prospectus supplement and any relevant free writing prospectus or term sheet for complete details. You may get these documents for free by visiting the SEC web site at www.sec.gov. Alternatively, copies of the prospectus and the prospectus supplement may be obtained from (i) Citigroup Global Markets Inc. toll-free at 1-800-831-9146, (ii) Goldman Sachs & Co. LLC. toll-free at 1-866-471-2526, (iii) Barclays Capital Inc. toll-free at 1-888-603-5847 and (iv) Morgan Stanley & Co. LLC toll-free at 1-866-718-1649.
| * | The security ratings above are not a recommendation to buy, sell or hold the securities offered hereby. The ratings may be subject to revision or withdrawal at any time by Moody’s and S&P. Each of the security ratings above should be evaluated independently of any other security rating. |
Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded (other than any statement relating to the identity of the legal entity authorizing or sending this communication in a non-US jurisdiction). Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another e-mail system.
3